FFO
COGT icon

Fortitude Family Office’s Cogent Biosciences COGT Stock Holding History

Fortitude Family Office’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-105
Closed -$629 – 2047
2025
Q1 		$629 Hold
105
– – ﹤0.01% 1070
2024
Q4 		$819 Hold
105
– – ﹤0.01% 1160
2024
Q3 		$1.13K Hold
105
– – ﹤0.01% 1086
2024
Q2 		$885 Hold
105
– – ﹤0.01% 891
2024
Q1 		$706 Buy
+105
New +$649 ﹤0.01% 919

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fortitude Family Office's COGT Position: Q2 2025 in Review

Fortitude Family Office sold out of Cogent Biosciences (COGT) in Q2 2025, closing a stake of 105 shares — an estimated $629 sold.

Fortitude Family Office first reported a position in COGT in Q1 2024 and held it in 5 quarters. The position peaked at $1.13K in Q3 2024. 180 funds tracked by Wall St. Rank hold COGT as of Q2 2025.

  • Fortitude Family Office reported no remaining Cogent Biosciences position as of Q2 2025 after selling out during the quarter.
  • Fortitude Family Office sold 105 Cogent Biosciences shares in Q2 2025, an estimated $629.
  • Fortitude Family Office first reported a position in Cogent Biosciences in Q1 2024 and held it in 5 quarters.
  • Fortitude Family Office's Cogent Biosciences position peaked at $1.13K in Q3 2024.
  • 180 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2025.

Based on Fortitude Family Office's 13F filing for Q2 2025, filed 15 Jul 2025.